The Impact of Regulations, Safety Considerations and Physical Limitations on Research Progress at Maximum Biocontainment

We describe herein, limitations on research at biosafety level 4 (BSL-4) containment laboratories, with regard to biosecurity regulations, safety considerations, research space limitations, and physical constraints in executing experimental procedures. These limitations can severely impact the number of collaborations and size of research projects investigating microbial pathogens of biodefense concern. Acquisition, use, storage, and transfer of biological select agents and toxins (BSAT) are highly regulated due to their potential to pose a severe threat to public health and safety. All federal, state, city, and local regulations must be followed to obtain and maintain registration for the institution to conduct research involving BSAT. These include initial screening and continuous monitoring of personnel, controlled access to containment laboratories, accurate and current BSAT inventory records. Safety considerations are paramount in BSL-4 containment laboratories while considering the types of research tools, workflow and time required for conducting both in vivo and in vitro experiments in limited space. Required use of a positive-pressure encapsulating suit imposes tremendous physical limitations on the researcher. Successful mitigation of these constraints requires additional time, effort, good communication, and creative solutions. Test and evaluation of novel vaccines and therapeutics conducted under good laboratory practice (GLP) conditions for FDA approval are prioritized and frequently share the same physical space with important ongoing basic research studies. The possibilities and limitations of biomedical research involving microbial pathogens of biodefense concern in BSL-4 containment laboratories are explored in this review.

[1]  P. Snoy Establishing Efficacy of Human Products Using Animals , 2010, Veterinary pathology.

[2]  Kyle White,et al.  A computerized data-capture system for animal biosafety level 4 laboratories. , 2011, Journal of the American Association for Laboratory Animal Science : JAALAS.

[3]  Gretchen L. Demmin,et al.  Clinical laboratories, the select agent program, and biological surety (biosurety). , 2006, Clinics in laboratory medicine.

[4]  Filoviruses: A Compendium of 40 Years of Epidemiological, Clinical, and Laboratory Studies , 2009, Emerging Infectious Diseases.

[5]  P. Rollin,et al.  Cytokine measurement in biological samples after physicochemical treatment for inactivation of biosafety level 4 viral agents , 1999, Journal of medical virology.

[6]  T. Ksiazek,et al.  High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings. , 2007, The Journal of infectious diseases.

[7]  M. Kortepeter,et al.  Managing Potential Laboratory Exposure to Ebola Virus by Using a Patient Biocontainment Care Unit , 2008, Emerging infectious diseases.

[8]  Casey Skvorc,et al.  Developing a behavioral health screening program for BSL-4 laboratory workers at the National Institutes of Health. , 2011, Biosecurity and bioterrorism : biodefense strategy, practice, and science.

[9]  J. Peiris,et al.  Detection of highly pathogenic influenza and pandemic influenza virus in formalin fixed tissues by immunohistochemical methods. , 2012, Journal of virological methods.

[10]  R. Schoepp,et al.  Detection of viral RNA from paraffin-embedded tissues after prolonged formalin fixation. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[11]  Jamie A. Blow,et al.  Virus inactivation by nucleic acid extraction reagents. , 2004, Journal of virological methods.

[12]  H. Feldmann,et al.  Framework for Leadership and Training of Biosafety Level 4 Laboratory Workers , 2008, Emerging infectious diseases.

[13]  Kathleen Carr,et al.  Implementation of biosurety systems in a Department of Defense medical research laboratory. , 2004, Biosecurity and bioterrorism : biodefense strategy, practice, and science.

[14]  J. McCormick,et al.  Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation , 1982, Journal of clinical microbiology.